Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, Litzow MR, Erba HP.

Leuk Res. 2019 Mar;78:29-33. doi: 10.1016/j.leukres.2019.01.007. Epub 2019 Jan 17.

PMID:
30673620
2.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Jan 18. pii: blood-2018-10-881961. doi: 10.1182/blood-2018-10-881961. [Epub ahead of print]

PMID:
30658992
3.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG.

Nat Genet. 2019 Feb;51(2):296-307. doi: 10.1038/s41588-018-0315-5. Epub 2019 Jan 14.

PMID:
30643249
4.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2018 Dec 18. pii: S1083-8791(18)30890-5. doi: 10.1016/j.bbmt.2018.12.068. [Epub ahead of print]

PMID:
30576834
5.

Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL.

Wendorff AA, Quinn SA, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, Litzow MR, Tallman MS, Paietta E, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Rabadan R, Van Vlierberghe P, Ferrando AA.

Cancer Discov. 2018 Dec 19. doi: 10.1158/2159-8290.CD-18-1005. [Epub ahead of print]

PMID:
30567843
6.

Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant.

Torres ME, Hashmi SK, Stevens MA, Tan AD, Callahan V, Sloan JA, Hogan WJ, Litzow MR, Roy V, Foran JM, Colon-Otero G.

Hematol Oncol Stem Cell Ther. 2018 Dec 9. pii: S1658-3876(18)30118-3. doi: 10.1016/j.hemonc.2018.11.004. [Epub ahead of print]

7.

No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

Jain T, Litzow MR.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):25-34. doi: 10.1182/asheducation-2018.1.25. Review.

PMID:
30504288
8.

No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

Jain T, Litzow MR.

Blood Adv. 2018 Nov 27;2(22):3393-3403. doi: 10.1182/bloodadvances.2018020198. Review.

9.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high dose anthracycline: subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

Haematologica. 2018 Nov 22. pii: haematol.2018.197277. doi: 10.3324/haematol.2018.197277. [Epub ahead of print]

10.

Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?

Litzow MR.

Best Pract Res Clin Haematol. 2018 Dec;31(4):357-360. doi: 10.1016/j.beha.2018.09.004. Epub 2018 Sep 20. Review.

PMID:
30466747
11.

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2018 Nov 10. pii: S1083-8791(18)30698-0. doi: 10.1016/j.bbmt.2018.11.004. [Epub ahead of print]

PMID:
30423480
12.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W.

Blood Adv. 2018 Nov 13;2(21):2922-2936. doi: 10.1182/bloodadvances.2018024844.

13.

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors.

Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE.

Haematologica. 2018 Oct 31. pii: haematol.2018.200121. doi: 10.3324/haematol.2018.200121. [Epub ahead of print]

14.

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.

Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS.

Am J Hematol. 2019 Jan;94(1):111-117. doi: 10.1002/ajh.25333. Epub 2018 Nov 15.

PMID:
30370956
15.

Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy.

Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, Alkhateeb HB, Patnaik MS, Hogan WJ, Litzow MR, Al-Kali A.

Ann Hematol. 2019 Feb;98(2):331-337. doi: 10.1007/s00277-018-3509-0. Epub 2018 Oct 18.

PMID:
30334068
16.

A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors.

Yan F, Al-Kali A, Zhang Z, Liu J, Pang J, Zhao N, He C, Litzow MR, Liu S.

Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.

17.

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.

Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 Feb;25(2):270-278. doi: 10.1016/j.bbmt.2018.09.004. Epub 2018 Oct 3.

PMID:
30292009
18.

Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin.

Lehman JS, Dasari S, Damodaran SS, El-Azhary RA, Gibson LE, Hashmi SK, Hogan WJ, Kenderian SJ, Patnaik MS, Litzow MR, Lazarus HM, Meves A.

Clin Exp Dermatol. 2018 Oct 2. doi: 10.1111/ced.13759. [Epub ahead of print]

PMID:
30280423
19.

Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.

Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, Litzow MR, Alkhateeb HB.

Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1509318. [Epub ahead of print]

PMID:
30277111
20.

A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.

Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 Dec;93(12):E401-E404. doi: 10.1002/ajh.25290. Epub 2018 Oct 17. No abstract available.

PMID:
30230610
21.

Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes.

Alkharabsheh O, Saadeh SS, Patnaik MS, Alkhateeb H, Gangat N, Begna KH, Hogan WJ, Greipp PT, He R, Nguyen PL, Litzow MR, Al-Kali A.

Am J Hematol. 2018 Dec;93(12):E398-E401. doi: 10.1002/ajh.25287. Epub 2018 Oct 9. No abstract available.

PMID:
30218541
22.

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.

Biol Blood Marrow Transplant. 2019 Jan;25(1):73-85. doi: 10.1016/j.bbmt.2018.08.018. Epub 2018 Aug 25.

PMID:
30153491
23.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2018 Aug 23;3(16). pii: 124015. doi: 10.1172/jci.insight.124015. [Epub ahead of print] No abstract available.

24.

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Leuk Res. 2018 Sep;72:92-95. doi: 10.1016/j.leukres.2018.08.005. Epub 2018 Aug 10. No abstract available.

PMID:
30118897
25.

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G.

Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018 Aug 16.

26.

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK.

Leuk Res. 2018 Nov;74:130-136. doi: 10.1016/j.leukres.2018.07.016. Epub 2018 Jul 19.

PMID:
30055822
27.

Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts.

Mangaonkar AA, Gangat N, Al-Kali A, Elliott MA, Begna KH, Hanson CA, Ketterling RP, Wolanskyj-Spinner AP, Hogan WJ, Litzow MR, Patnaik MM.

Leuk Res. 2018 Aug;71:60-62. doi: 10.1016/j.leukres.2018.07.010. Epub 2018 Jul 11.

PMID:
30015104
28.

Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia.

Hefazi M, Litzow MR.

Curr Hematol Malig Rep. 2018 Aug;13(4):265-274. doi: 10.1007/s11899-018-0455-9. Review.

PMID:
29948644
29.

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.

Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS.

Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25162. [Epub ahead of print]

PMID:
29905379
30.

Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA.

Mayo Clin Proc. 2018 Oct;93(10):1363-1374. doi: 10.1016/j.mayocp.2018.04.013. Epub 2018 Jun 14.

PMID:
29866419
31.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.

32.

Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions.

Hefazi M, Langer KJ, Khera N, Adamski J, Roy V, Winters JL, Gastineau DA, Jacob EK, Kreuter JD, Gandhi MJ, Hogan WJ, Litzow MR, Hashmi SK, Yadav H, Iyer VN, Scott JP, Wylam ME, Cartin-Ceba R, Patnaik MM.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1906-1913. doi: 10.1016/j.bbmt.2018.04.012. Epub 2018 Apr 18.

PMID:
29679771
33.

HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia.

Shen N, Yan F, Pang J, Gao Z, Al-Kali A, Haynes CL, Litzow MR, Liu S.

ACS Appl Mater Interfaces. 2018 May 2;10(17):14454-14462. doi: 10.1021/acsami.8b01696. Epub 2018 Apr 18.

PMID:
29668254
34.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219. [Epub ahead of print] No abstract available.

PMID:
29667455
35.

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Blood Cancer J. 2018 Mar 7;8(3):29. doi: 10.1038/s41408-018-0067-6.

36.

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.

Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, Litzow MR, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Feb 12;8(2):18. doi: 10.1038/s41408-018-0051-1. No abstract available.

37.

Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state.

Saadeh SS, Litzow MR.

Expert Rev Hematol. 2018 Mar;11(3):195-207. doi: 10.1080/17474086.2018.1433030. Epub 2018 Feb 7. Review.

PMID:
29376437
38.

Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine.

Sterner RM, Kremer KN, Al-Kali A, Patnaik MM, Gangat N, Litzow MR, Kaufmann SH, Westendorf JJ, van Wijnen AJ, Hedin KE.

Oncotarget. 2017 Oct 10;8(55):94569-94579. doi: 10.18632/oncotarget.21809. eCollection 2017 Nov 7.

39.

Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

Cummins NW, Rizza S, Litzow MR, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgrefe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD.

PLoS Med. 2017 Nov 28;14(11):e1002461. doi: 10.1371/journal.pmed.1002461. eCollection 2017 Nov.

40.

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP.

Am J Hematol. 2018 Feb;93(2):E49-E52. doi: 10.1002/ajh.24980. Epub 2017 Dec 4. No abstract available.

41.

Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series.

Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S.

Mayo Clin Proc. 2017 Nov;92(11):1617-1624. doi: 10.1016/j.mayocp.2017.08.016. Epub 2017 Nov 1.

PMID:
29101931
42.

Efficacy of biological agents in the treatment of Erdheim-Chester disease.

Goyal G, Shah MV, Call TG, Litzow MR, Wolanskyj-Spinner AP, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Hook CC, Hogan WJ, Go RS.

Br J Haematol. 2018 Nov;183(3):520-524. doi: 10.1111/bjh.14997. Epub 2017 Oct 30. No abstract available.

PMID:
29082516
43.

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.

Haddox CL, Mangaonkar AA, Chen D, Shi M, He R, Oliveira JL, Litzow MR, Al-Kali A, Hogan WJ, Elliott MA.

Blood Cancer J. 2017 Sep 15;7(9):e607. doi: 10.1038/bcj.2017.89. No abstract available.

44.

A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.

Yan F, Shen N, Pang JX, Zhao N, Zhang YW, Bode AM, Al-Kali A, Litzow MR, Li B, Liu SJ.

Leukemia. 2018 Apr;32(4):865-873. doi: 10.1038/leu.2017.307. Epub 2017 Oct 10.

45.

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.

Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT Jr, Trippett T, Duell J, Bargou RC, Holland C, Benjamin JE, Klinger M, Litzow MR.

Leukemia. 2018 Feb;32(2):562-565. doi: 10.1038/leu.2017.306. Epub 2017 Oct 9. No abstract available.

46.

Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods.

Lehman JS, Hashmi SK, Lazarus HM, El-Azhary RA, Gibson LE, Hogan WJ, Litzow MR, Patnaik MS, Buadi F, Lacy MQ, Dasari S, Vanderboom P, Meves A.

J Cutan Pathol. 2017 Dec;44(12):1087-1091. doi: 10.1111/cup.13019. Epub 2017 Sep 14. No abstract available.

47.

A systematic review of religious beliefs about major end-of-life issues in the five major world religions.

Chakraborty R, El-Jawahri AR, Litzow MR, Syrjala KL, Parnes AD, Hashmi SK.

Palliat Support Care. 2017 Oct;15(5):609-622. doi: 10.1017/S1478951516001061. Review.

48.

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE.

Bone Marrow Transplant. 2017 Oct;52(10):1372-1377. doi: 10.1038/bmt.2017.164. Epub 2017 Sep 4.

PMID:
28869617
49.

Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set.

Goyal G, Bartley AC, Patnaik MM, Litzow MR, Al-Kali A, Go RS.

Blood Cancer J. 2017 Aug 25;7(8):e592. doi: 10.1038/bcj.2017.79. No abstract available.

50.

Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia.

Shen N, Yan F, Pang J, Zhao N, Gangat N, Wu L, Bode AM, Al-Kali A, Litzow MR, Liu S.

Clin Cancer Res. 2017 Oct 15;23(20):6254-6266. doi: 10.1158/1078-0432.CCR-17-0235. Epub 2017 Jul 18.

Supplemental Content

Loading ...
Support Center